

CST Bulletin – April, 2022

BC Cancer ST Program Updates for April, 2022

AFFECTED APPLICATION(S)	PowerChart: Oncology/Hematology Regimens and PowerPlans
AFFECTED AREA(S)	BC Cancer VC (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build

What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- <u>For PowerPlans that are versioned</u>: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop up window will appear to indicate a new version is required.
 - o Click Yes to accept the new version
 - o **Do not** use the Copy Forward functionality to ensure that the updates apply

ZONCP BR BRAVA7 - Cycle 1	Orders			*Est. Start Date: 27-Oct-2021 08:00 PD Repeat
22ONCP BR BRAVA7 - Cycle 2	A new version of this plan is available. Would you like to sele	oct the new v	ersion?	*Est. Start Date: 17-Nov-2021
zzONCP BR BRAVA7 - Cycle 3	A new restort of this plan is available. Would you like to see	et the new v		Skip *Est. Start Date: 08-Dec-2021
22ONCP BR BRAVA7 - Cycle 4	Ves		No	*Est. Start Date: 29-Dec-2021
22ONCP BR BRAVA7 - Cycle 5	16		NO	*Est. Start Date: 19-Jan-2022
22ONCP BR BRAVA7 - Cycle 6				*Est. Start Date: 09-Feb-2022
22ONCP BR BRAVA7 - Cycle 7				*Est. Start Date: 02-Mar-2022
謬 zzONCP BR BRAVA7 - Cycle 8				*Est. Start Date: 23-Mar-2022

• **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning)

Please see this month's changes below.



PowerPlan: LYIT

Cycles/PowerPlans: LYIT (Weekly Option), LYIT (Twice Weekly Option), LYIT (Single Dose Option)

Changes:

The PowerPlan and Regimen names has been updated for Weekly and Twice Weekly options.

- The original LYIT PowerPlan and Regimen are renamed with Twice Weekly Option
- New PowerPlan and Regimen are created for the Weekly Option

CNC LY LYIT (Twice Weekly Option)

CNC LY LYIT (Weekly Option)

SONCP LY LYIT (Single Dose Option)

NCP LY LYIT (Twice Weekly Option)

CONCP LY LYIT (Weekly Option)

ONCP LY LYIT Pretreatment Plan

In the Chemotherapy phase of all PowerPlans, the yellow note was added for "Refer to local guidelines for anticoagulation management"

	🏈 Treatment Regimen
	I refer to local guidelines for anticoagulation management
P	Stero Time
	S methotrexate (methotrexate - oncology)
	12 mg, intrathecal, once oncology, drug form: inj
	Intrathecal Use Only. Days 1, 8, 15
	🔗 cytarabine (cytarabine - oncology)
	50 mg, intrathecal, once oncology, drug form: inj
	Intrathecal Use Only. Days 4, 11, 18

In the Chemotherapy phase of LYIT (Weekly Option), methotrexate (Days 1, 15, 29) and cytarabine (Days 8, 22, 36) are to be administered weekly

				Day 1	Day 8	Day 15	Day 22	Day 29	Day 36
	R	17	Component	Future Pending					
	00	Y	Component	*Est. 16-Mar-2022 08:	*Est. 23-Mar-2022 08:	*Est. 30-Mar-2022 08:	*Est. 06-Apr-2022 08:	*Est. 13-Apr-2022 08:	*Est. 20-Apr-2022 08:
				Actions 🔻					
			O Treatment Regimen						
			Refer to local guidelines for anticoagulation management						
M	1	0	📌 Zero Time	0 hr					
				Planned	Planned	Planned	Planned	Planned	Planned
2	1	0	😁 methotrexate (methotrexate - oncology)	0 min		0 min		0 min	
			12 mg, intrathecal, once oncology, drug form: inj						
			Intrathecal Use Only. Days 1, 15, 29	Planned		Planned		Planned	
7	1	0	📌 cytarabine (cytarabine - oncology)		0 min		0 min		0 min
			50 mg, intrathecal, once oncology, drug form: inj						
			Intrathecal Use Only. Days 8, 22, 36		Planned		Planned		Planned

In the Labs phase of LYIT (Weekly Option), all lab orders are ordered prior to each days of treatment (Days 8, 15, 22, 29, 36, 43)

ONCP LY L	YIT (Weekly Option) - Cycle 1, Labs (Day 8, 15, 22, 29, 36, 43) (Future Pending)	*Est. 22-Mar-2022 08:0	0 PDT - 42 Days				
		Day 8	Day 15	Day 22	Day 29	Day 36	Day 43
A 60	Component	Future Pending	Future Pending	Future Pending	Future Pending	Future Pending	Future Pending
0.0	Component	*Est. 22-Mar-2022 08:	*Est. 29-Mar-2022 08:	*Est. 05-Apr-2022 08:	*Est. 12-Apr-2022 08:	*Est. 19-Apr-2022 08:	*Est. 26-Apr-2022 08:
		Actions 💌	Actions 🕶	Actions 🔻	Actions 🔻	Actions 💌	Actions 🕶
P	🔀 CBC and Differential						
	Blood, once, Order for future visit	Planned	Planned	Planned	Planned	Planned	Planned
V	🔭 PTT						
	Blood, once, Order for future visit	Planned	Planned	Planned	Planned	Planned	Planned
V	🖄 INR						
	Blood, once, Order for future visit	Planned	Planned	Planned	Planned 💻	Planned	Planned





In the Scheduling phase of LYIT (Weekly Option), all scheduling orders are ordered for each days treatment (Days 1, 8, 15, 22, 29, 36)

	<u>⁄&</u>	For ambulatory clinic administration, select the orders below:	
ī		Intrathecal Chemotherapy Visit	Within 2 Weeks
1		induced chemotherapy visit	Day 1
1	en 🗖	Intrathecal Chemotherapy Visit	Within 2 Weeks
1	~ 1	indatriecal chemotherapy visit	Day 8
1	es 🛱	Intrathecal Chemotherapy Visit	Within 2 Weeks
	99 M	intratriecal Chemotherapy visit	Day 15
1	P	Intrathecal Chemotherapy Visit	Within 2 Weeks
]	69 🔽	Intrathecal Chemotherapy visit	Day 22
]	🖎		
	69 🔽	Intrathecal Chemotherapy Visit	Within 2 Weeks
-	<u>(</u>		Day 29
	69 🖊	Intrathecal Chemotherapy Visit	Within 2 Weeks
	10		Day 36
		For Interventional Radiology administration, select the orders below:	
	eə 才	IR Lumbar Puncture with Injection	Routine, Order for future visit
	_		Day 1
	eə 💆	IR Lumbar Puncture with Injection	Routine, Order for future visit
			Day 8
	eə 🖄	IR Lumbar Puncture with Injection	Routine, Order for future visit
			Day 15
1	69 📝	IR Lumbar Puncture with Injection	Routine, Order for future visit
	-		Day 22
1	eə 🕅	IR Lumbar Puncture with Injection	Routine, Order for future visit
	-	,	Day 29
1	eə 🕅	IR Lumbar Puncture with Injection	Routine, Order for future visit
	ك	······································	Day 36

In the Chemotherapy phase for LYIT (Twice Weekly Option), Pre-Chemo Metrics have been separated between Days 1, 8, 15 and Days 4, 11, 18.

Operation of the second sec
I way proceed with treatment on Day 1, Day 8, and Day 15 if:
I veutrophils Greater Than or Equal to 0.5 x 10^9/L within 24 hours
🏈 Platelet Count Greater Than or Equal to 50 x 10^9/L within 24 hours
🚱 INR Less Than 1.5 within 24 hours
🚱 PTT Less Than or Equal to ULN within 24 hours
It is a construction of the set o
🏈 Platelet Count Greater Than or Equal to 50 x 10^9/L within 24 hours
🚱 INR Less Than 1.5 within 24 hours
🚱 PTT Less Than or Equal to ULN within 24 hours

In the Labs phase of LYIT (Twice Weekly Option), all lab orders are ordered prior to each days of treatment (Day 4, 8, 11, 15, 18, 22)

		Day 4	Day 8	Day 11	Day 15	Day 18	Day 22
\$ 17 0	Component	Future Pending					
00,00	Component	*Est. 18-Mar-2022 08:	*Est. 22-Mar-2022 08:	*Est. 25-Mar-2022 08:	*Est. 29-Mar-2022 08:	*Est. 01-Apr-2022 08:	*Est. 05-Apr-2022 08:
		Actions 🔻					
	🔭 CBC and Differential						
	Blood, once, Order for future visit		Planned	Planned	Planned	Planned	Planned
	🔁 РТТ						
В	Blood, once, Order for future visit		Planned	Planned	Planned	Planned	Planned
	🖄 INR						
B	Blood, once, Order for future visit		Planned	Planned	Planned	Planned	Planned

Versioning: Y

TRANSFORMATIONAL

Jira: CST-161171



A joint initiative of: Vancouver Coastal Health, the Provincial Health Services Authority, and Providence Health Care

PowerPlan: LYVIPDF	RT
Cycles/PowerPlans:	LYVIPDRT cycles 2 to 4
Changes:	
	iption in the Prescriptions phase
	ycle 2, Prescriptions (Future Pending)
e dexamethasone	40 mg, PO, as directed, Take daily on days 1-4 of each cycle, drug form: tab, dispense qty: 21 day Prescription is part of a combined IV/PO protocol. Dispense quantity = 1 cycle
🗹 📲 🛄 mesna	480 mg/m2, PO, as directed, 4 and 8 hours after ifosfamide infusion on days 1 to 3. To be taken at home in 1 cu Round dose to nearest 10 mg. Prescription is part of a combined IV/PO protocol. Pharmacy to prepare 2 doses
	mesna Details: 480 mg/m2, PO, as directed, 4 and 8 hours after ifosfamide infusion on days 1 to 3. To be taken at home in 1 cup of carbonated beverage over 15 minutes, drug form: syringe-oral, dispense qty: 21 day Order Comment: Round dose to nearest 10 mg. Prescription is part of a combined IV/PO protocol. Pharmacy to prepare 2 doses daily for outpatient use. Dispense quantity = 1 cycle
ONCP LY LYVIPDRT Cycles 2 to 4 - Cycle 2, Prescrip	40 mg, PO, qdaily with breakfast, order duration: 4 doses or times, drug form: tab
	Medication is part of a combined IV/PO protocol. Days 1 to 4 480 mg/m2, PO, q4h oncology, order duration: 2 doses or times, drug form: syringe-oral, start: T;N+420
	4 and 8 hours after completion of ifosfamide. To be given in 1 cup of carbonated beverage over 15 minutes. Round dose to nearest 10 mg. Medication is part of a combined IV/P 480 mg/m2, PO, q4h oncology, order duration: 2 doses or times, drug form: syringe-oral, start: T+ 1;N+420
🗆 📲 🙀 🔗 mesna	4 and 8 hours after completion of ifosfamide. To be given in 1 cup of carbonated beverage over 15 minutes. Round dose to nearest 10 mg. Medication is part of a combined IV/P 480 mg/m2, PO, q4h oncology, order duration: 2 doses or times, drug form: syringe-oral, start: T+2;N+420 4 and 8 hours after completion of ifosfamide. To be given in 1 cup of carbonated beverage over 15 minutes. Round dose to nearest 10 mg. Medication is part of a combined IV/P mesna
	Details: 480 mg/m2, P0, 94h oncology, order duration: 2 doses or times, drug form: syringe-oral, start: 7 ±2:N+420 Order Comment: 4 and 8 hours after completion of ifosfamide. To be given in 1 cup of carbonated beverage over 15 minutes. Round dose to nearest 10 mg. Medication is part of a combined IV/PO protocol. Day 3
Versioning: Yes	
Jira: CST-161170	





A joint initiative of: Vancouver Coastal Health, the Provincial Health Services Authority, and Providence Health Care

PowerPlan: GOTDEMACO

Cycles/PowerPlans: GOTDEMACO outpatient (day 8 only) + GOTDEMACO (inpatient and outpatient)

Changes:

Removed Day 8 pre chemo metrics for neutrophils, platelet count, and creatinine in the outpatient chemotherapy phase of both Powerplans.

E Link to Protocol: Therapy for High Risk Gestational	st. 18-Mar-2022 08: Actions ▼
🖄 🖉 Link to Brotocoly Therapy for High Pick Contational	Actions
Trophoblastic Neoplasia (GTN) using Etoposide, Methotrexate, Leucovorin (Folinic Acid), DACTINomycin, Cyclophosphamide and vinCRIStine	
This plan is for outpatient Day 8 treatment only. Patient to receive Day 1 and Day 2 as an inpatient (refer to proto	
Pre-Medications	
Patient to take own supply of pre-medications. RN/Pharmacist to confirm	
🗹 🔗 ondansetron	-30 min
Versioning: Yes	

PowerPlan: LYCODOXMR

Cycles/PowerPlans: LYCODOXMR (inpatient)

Changes:

In the IR Scheduling for Intrathecal Chemo phase, an IR lumbar puncture with injection order for Day 19 was added

ONCP L	Y LYCODOXMR (Inpatient) - Cycle 2, IR Scheduling for Intrati	
	IR Lumbar Puncture with Injection	Routine, Reason: Intrathecal chemotherapy administration, Order for future visit Day 3
	IR Lumbar Puncture with Injection	Routine, Reason: Intrathecal chemotherapy administration, Order for future visit Day 19
	Ensure Intrathecal Chemotherapy orders are completed	d (see Intrathecal Chemotherapy Phases)

A new Intrathecal Chemotherapy phase was added for Day 19. Contents are same as Day 3 phase.





Pertestment Lab: PIT Blood, Routine, Unit collect, once, Order for future visit Planned Pitts Blood, Routine, Unit collect, once, Order for future visit Planned Perc-Chemo Metrics Gree cytarabile of for perployed blosts (scute leutemia) and Platelet Count greater than 50 x 10 9/L Planned Physican may tata in trathecal chemotherapy with Cycle 1 fr high risk of CNS disease Physican may tata in trathecal chemotherapy with Cycle 1 fr high risk of CNS disease Physican may tata in trathecal chemotherapy with Cycle 1 fr high risk of CNS disease Physican may tata in trathecal chemotherapy with a minimum of 4B hours between do Physican may tata in trathecal chemotherapy with a minimum of 4B hours between do Physican may tata in trathecal chemotherapy with or thrombosis (e.g., scute thrombosis, less than 30 days from Bit doss) Planned Phanned to be procedure and resumed the day stret the procedure, and resuming the day after the procedure. Planned Pertor CSF (CSF Cell Court and Differen	8	0	~	Component	Future Pending *Est. 17-Mar-2022 15: Actions ▼	
Elicod, Routine, Unit collect, once, Order for future visit Planned Image: Control of the second s				Pretreatment Labs		
■ Nik Blood, Routine, Unit collect, once, Order for future visit Planned ● Pre-Chermo Metrics ● Give cytrarbine if no peripheral blasts (acute leukemia) and Platelet Count greater than 30x 100/L ● Nik Russ Than 1.5 and PTL Less Than or Equal to UUN ● Treatment Regimen ● Physician may start intrafhecal chemotherapy with Cycle 11 flipp inks of CNS disease ● Physician may start intrafhecal chemotherapy with Cycle 11 flipp inks of CNS disease ● Physician may change the days of Intrafhecal chemotherapy with a minimum of 48 hours between do C A total of 8 doses of IT chemotherapy should be given for all patients undergoing MARGATH protocol (those with CNS disease may require more than 11 dose) ● Therapeutic dateparin. MD to write separate order for holding therapeutic, LINWH should be held 36 hours prior to the procedure and resumed the day after the procedure - In patients all high hisk of thrombosis (e.g., acute thrombosis, less than 30 days from diagnosis of VTB, MD may consider changing to BD dosing and giving half the therapeutic dose of IDMWH at 24 hours piont to the group creating and examing the day after the procedure expectedure, and resuming the day after the procedure expectedure, and resuming the day after the procedure expectedure. And examples the on diagnosis of VTB, MD may consider changing to BD dosing and giving half the therapeutic dose of IDMWH at 24 hours piont to the efficience SE (CSF Cell Count and Differen4 hr Creatorspinal Fluid Labat ● Planned ● Device SE (CSF Cell Count and Differen4 hr Creatorspinal Fluid Labat ● Planned ● Planned ● Device SE (CSF Cell Protetin) - 4 hr Creatorspinal Fluid, Routine, Unit collect	7			🕈 РТТ		
Biood, Rotine, Unit collect, once, Order for future visit Planned Pre-Cherno Metrics For exchanno Metrics Status Give cytarabine if no peripheral blasts (acute leukemia) and Platelet Court greater than 30x 10 9/L Physican may stan dTT Less Than 15 and PTL Less Than 15 and 15					Planned	
Pre-Chemo Metrics Give cytratabine if no peripheral blasts (acute leukemia) and Platelet Count greater than 30x 10 9/L INR Less Than 1.5 and PTT Less Than or Equal to ULN Treatment Regimen Physician may star intrathecal chemotherapy with Cycle 1 fi high risk of CNS disesse Physician may change the days of Intrathecal chemotherapy with a minimum of 48 hours between do CNS disesse may require more than 81 doses! Control of Biologic Soft I chemotherapy should be given for all patients undergoing MAGRATH protocol (those with CNS disesse may require more than 81 doses!) Therapeutic dalteparin: MD to write separate order for holding therapeutic anticoagulation according to the following guidelines: - Once daily therapeutic, LMWH should be held 36 hours prior to the procedure and resumed the day after the procedure. - In patients at high risk of thrombosis (e.g., acute thrombosis, less than 30 days from inj intrathecal use Only Consider changing to BID dosing and giving half the threapeutic duce OI LMWH at 24 hours prior to the procedure, and resuming the day after the procedure Consider changing to BID dosing and giving half the threapeutic duce OI LMWH at 24 hours prior to the procedure, and resuming the day after the procedure Constrate-conspinal Fluid Labs Cerebrospinal Fluid Labs Call Court CSF (CSF Cell Count and Differen 44 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T/N, en Planned Cill Court CSF (CSF Casi / Collection: T/N, en Planned Cill Court CSF (CSF Casi / Collection: T/N, en	7					
Image: Size cytanoline if no peripheral blasts (acute leukemia) and Patelet Count preserts than 30 k1091. INR Less Than 1.5 and PTT Less Than or Equal to ULN Image: Testimetin Regimen Image: Physician may start intrathecal chemotherapy with Cycle 1 if high risk of CNS disesse Image: Physician may start intrathecal chemotherapy with 2 with a minimum of 48 hours between do Image: Physician may start intrathecal chemotherapy should be given for all patients undergoing MAGRATH protocol (those with CNS disesse may require more than 81 floses) Image: Therapeutic dateparin: MD to write separate order for holding therapeutic anticoagulation according to the following guidelines: Image: Once daily therapeutic, LMWH should be held 36 hours procedure Image: Once daily therapeutic anticoagulation according to the procedure and resummed the day after the procedure Image: Once daily therapeutic anticoagulation according to the procedure and resummed the day after the procedure Image: Once daily therapeutic (LMWH should be held 36 hours procedure and resumming the day after the procedure Image: Once daily therapeutic (LMWH should be held 36 hours procedure and resumming the day after the procedure Image: Once daily therapeutic (LMWH should be held 36 hours procedure and resumming the day after the procedure Image: Once daily therapeutic (LMWH should be held 36 hours procedure and resumming the day after the procedure Image: Once daily therapeutic (LMWH should be held 36 hours procedure and resumming the day after the procedur					Planned	
 and Platelet Count greater than 50x 10 9/L Treatment Regimen Physician may start intrathecal chemotherapy with Cycle 1i fhigh risk of CNS disease Physician may change the days of Intrathecal chemotherapy with a minimum of 48 hours between do A total of 8 doses of IT chemotherapy should be given for A total of 8 doses of IT chemotherapy should be given for A total of 8 doses of IT chemotherapy should be given for A total of 8 doses of IT chemotherapy should be given for holding therapeutic, alteroguids MAGRAH Protocol (those with CNS disease may require more than 8 IT doses) Therapeutic datepatin: MD to write separate order for holding therapeutic, alteroguids maccording to the following guidelines: Once daily therapeutic, LINWH should be held 36 hours prior to the procedure and resumed the day after the procedure, and resumed the day after the procedure, and resumed the day after the proceedure. In patients at high risk of thrombosis (e.g., acute thrombosis, less of LINWH at 24 hours prior to the procedure of LINWH at 24 hours prior to the procedure. Strathine (C) tratable - oncology) 4 hr Strathecal Use Only Protein CSF CEI Count and Differen +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T/N, on Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T/N, on Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T/N, on Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T/N, on Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T/N, on Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T/N, on Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T/N, on Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T/N, on Planned Cerebrospinal fluid, Routi						
 INR Less Than 1.5 and PTI Less Than or Equal to ULN Testment Regimen Physician may start intrathecal chemotherapy with Cycle 1f high nisk of CNS disesse Physician may start intrathecal chemotherapy with Cycle 1f high nisk of CNS disesse Physician may start intrathecal chemotherapy with Cycle 1f high nisk of CNS disesse Physican may change the days of Intrathecal chemotherapy with a minimum of 48 hours between do A total of 8 doses of IT chemotherapy should be given for all patients undergoing MAGRATH protocol (those with CNS disesse may require more than 8 IT doses) Therapeutic datteparin: M1 to write separate order for holding therapeutic, LMWH should be held 36 hours prior to the procedure and resumed the day after the procedure - In patients at high nisk of thrombosis (e.g., acute thrombosis, less than 30 days from diagnosis of VTE), MD may consider changing to 810 dosing and giving into the procedure, and resumed the day after the procedure cytarabine (cytarabine - oncology)						
 Treatment Regimen Physician may start intrathecal chemotherapy with Cycle I if high risk of CNS disease Physician may change the days of Intrathecal chemotherapy with a minimum of 48 hours between do A total of 8 doses of IT chemotherapy should be given for all patients undergoing MAGRATH protocol (those with CNS disease may require more than 8 IT dose) Therapeutic daltepatin: MD to write separate order for holding therapeutic, LNWH should be held 36 hours prior to the procedure and resumed the day after the procedure In patients at high risk of thrombosis (e.g., acute thombosis, less than 30 days from diagnosis of VTE), MD may consider changing to BID dosing and giving half the therapeutic dose of LMWH should be held 36 hours prior to the procedure and resumed the day after the procedure, and resuming the day after the procedure Cystarbine (cytarabine - oncology) 44 hr Stom, intrathecal, lone oncology, drug form: inj Intrathecal Use Only Bed rest for 30 minutes after procedure in supine position Cerebrospinal Fluid, Routine, Unit collect, Collection: TA, on Protein CSF (CSF Ciel Count and Differen			,			
 1 if high risk of CNS disease Physician may change the days of Intraffical chemotherapy with a minimum of 48 hours between do A total of 8 doses of IT chemotherapy should be given for all patients undergoing MACRATH protocol (those with CNS disease may require more than 8 IT doses) Therapeutic dalleparin: MD to write separate order for holding therapeutic, altikeparitic AD to write separate order for holding therapeutic, LMWH should be held 36 hours prior to the procedure and resumed the day after the procedure. In patients at high risk of thrombosis (e.g., acute thrombosis, less than 30 days from diagnosis of VTB, MD may consider changing to 8ID dosing and giving half the therapeutic dose of LMWH at 24 hours prior to the procedure, and resuming the day after the procedure cytarabine (sytarabine - oncology) 4 hr g cytarabine (sytarabine - oncology) G cytarabine (sytarabine - oncology) G Cell Count CSF (CSF Cell Count and Differen						
Chemotherapy with a minimum of 48 hours between do Image: A total of 8 does of IT chemotherapy should be given for all patients undergoing MAGRATH protocol (those with CNS disease may require more than 8 IT does) Image: A total of 8 does of IT chemotherapy should be pixel of the following guidelines: Image: One cally therapeutic anticoagulation according to the following guidelines: Image: One cally therapeutic, LMWH should be held 36 hours prior to the procedure and resumed the day after the procedure Image: One cally therapeutic, LMWH should be held 36 hours prior to the procedure and resumed the day after the procedure, and resuming the day after the procedure Image: One call of the call of the call of bours procedure, and resuming the day after the procedure Image: One call of the call of the call of bours procedure, and resuming the day after the procedure Image: One call of the ca			:			
all patients undergoing MAGRATH "protocol (those with CNS disease may require more than 8 IT doses) Therapeutic dalteparin: MD to write separate order for holding therapeutic, LMWH should be held 36 hours prior to the procedure and resumed the day after the procedure and resumed the day after the procedure, and resuming the day after the procedure cytarabine (cytarabine - oncology) (4 th re procedure, and resuming the day after the procedure cytarabine (cytarabine - oncology) (4 th re go cytarabine (cytarabine - oncology) (4 th re S0 mg, intrathecal, once oncology, drug form: inj Intrathecal Use Only Bed rest for 30 minutes after procedure in supine position Cerebrospinal Fluid Labs Cerebrospinal Fluid Labs Cerebrospinal fluid, Routine, Unit collect, Collection: T,N, on Planned Gi Glucose CSF Cerebrospinal fluid, Routine, Unit collect, Collection: T,N, on Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T,N, on Planned CSP Futhology Planned CSP Culture (CSP CAS) Cerebrospinal fluid, Routine, Unit collect, Collection: T,N, on Planned CSP Culture (CSP CAS) A th r Cerebrospinal fluid, Routine, Unit collect, Collection: T,N, on Planned CSP Culture (CSP CAS) A th r Cerebrospinal fluid, Routine, Unit collect, Collection: T,N, on Planned Planned CSP Culture (CSP CAS) A th r Cerebrospinal fluid, Routine, Unit collect, Collection: T,N, on Planned A the cerebrospinal fluid, Routine, Unit collect, Collection: T,N, on.			1			
 Therapeutic date pain: MD to write separate order for holding therapeutic anticoagulation according to the following guidelines: Once daily therapeutic, LINWH should be held 36 hours prior to the procedure and resumed the day after the procedure. In patients at high risk of thrombosis (e.g., acute thrombosis, less than 30 days from diagnosis of VTE), MD may consider changing to BID dosing and giving half the therapeutic dose of LINWH at 24 hours prior to the procedure, and resuming the day after the procedure. Optimize (cytarabine - oncology) 4 th procedure, and resuming the day after the procedure. Optimize (cytarabine - oncology) 4 thr Get rest for 30 minutes after procedure in supine position Cerebrospinal Fluid Labs Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Circerborspinal fluid, Routine, Unit collect, Collection: T;N, on Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Circerborspinal fluid, Routine, Unit collect, Collection: T;N, on Planned Pathology Non GYN Cytology Request (Path +4 hr AP Specimen CSF Pathology Planned Circ Cluture (SF C&S) +4 thr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Circ Cluture, CSF C&S) +4 thr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Circ Cluture (SF C&S) +4 thr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Circ Cluture (SF C&S) +4 thr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Circ Cluture (SF C&S) +4 thr Cerebrospinal fluid, R			;	all patients undergoing MAGRATH protocol (those with		
 In patients at high risk of thrombosis (e.g., acute thrombosis, less than 30 days from diagnosis of VTE), MD may consider changing to BID dosing and giving half the therapeutic dose of LMWH at 24 hours prior to the procedure, and resuming the day after the procedure Cytarabine (cytarabine - oncology) +4 hr S0 mg, intrathecal, once oncology, drug form: inj Intrathecal Use Only Ped rest for 30 minutes after procedure in supine position Cerebrospinal Fluid Labs Cell Count CSF (CSF Cell Count and Differen +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Glucose CSF + +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Glucose CSF + +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Pathology Non GYN Cytology Request (Path +4 hr AP Specimen CSF Pathology Immunophenotyping LPD (Immunophenoty +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned CSF Pathology Non GYN Cytology Request (Path +4 hr AP Specimen CSF Pathology Non GYN Cytology Request (Path +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Schedulable Orders Schedulable Orders Br Lumbar Puncture with Injection Routine, Reason: Intrathecal chemotherapy administration, Day 19 			:	Therapeutic dalteparin: MD to write separate order for holding therapeutic anticoagulation according to the following guidelines: Once daily therapeutic, LMWH should be held 36 hours prior to the procedure and resumed the day after the 		
S0 mg, intrathecal, once oncology, drug form: inj Intrathecal Use Only Planned				- In patients at high risk of thrombosis (e.g., acute thrombosis, less than 30 days from diagnosis of VTE), MD may consider changing to BID dosing and giving half the therapeutic dose of LMWH at 24 hours prior to the		
Intrathecal Use Only Planned Bed rest for 30 minutes after procedure in supine position Cerebrospinal Fluid Labs Cerebrospinal Fluid Labs Image: Cerebrospinal Fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Image: Cerebrospinal fluid, once, Order for future visit A S	7					
 Bed rest for 30 minutes after procedure in supine position Cerebrospinal Fluid Labs Cell Count CSF (CSF Cell Count and Differen <u>+4 hr</u> Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Protein CSF (CSF Total Protein) <u>+4 hr</u> Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Glucose CSF <u>+4 hr</u> Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Pathology Non GYN Cytology Request (Path <u>+4 hr</u> AP Specimen CSF Pathology Immunophenotyping LPD (Immunophenoty <u>+4 hr</u> Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned CSF Culture (CSF C&S) <u>+4 hr</u> Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Schedulable Orders IR Lumbar Puncture with Injection Routine, Reason: Intrathecal chemotherapy administration, Day 19 						
Image: Cerebrospinal Fluid Labs Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, once, Order for future visit Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Image: Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on					Planned	
 ✓ Cell Count CSF (CSF Cell Count and Differen +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned ✓ Protein CSF (CSF Total Protein) +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned ✓ Glucose CSF +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned ✓ Pathology Non GYN Cytology Request (Path +4 hr AP Specimen CSF Pathology ✓ Immunophenotyping LPD (Immunophenoty +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned ✓ CsF Culture (CSF C&S) +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned ✓ Schedulable Orders ✓ IR Lumbar Puncture with Injection Routine, Reason: Intrathecal chemotherapy administration, Day 19 				10 No.		
Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Protein CSF (CSF Total Protein) +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Glucose CSF +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Protein CSF (CSF Total Protein) +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Protein CSF Pathology Non GYN Cytology Request (Path +4 hr AP Specimen CSF Pathology CSF Pathology Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Protein CSF Cathure (CSF C&S) +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Cerebrospinal fluid, conce, Order for future visit 4 hr Cerebrospinal fluid, once, Order for future visit 4 hr Schedulable Orders	7	5		Y		
Image: Construct of the second state of the second sta					Planned	
✓ Glucose CSF +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned ✓ ✓ Pathology Non GYN Cytology Request (Path +4 hr AP Specimen SF Pathology Planned ✓ ✓ ✓ Immunophenotyping LPD (Immunophenoty +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned ✓ ✓ ✓ Immunophenotyping LPD (Immunophenoty +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned ✓ ✓ CSF Culture (CSF C&S) +4 hr Cerebrospinal fluid, once, Order for future visit ✓ ✓ Schedulable Orders ✓ ✓ IR Lumbar Puncture with Injection Routine, Reason: Intrathecal chemotherapy administration, Day 19 Day 19	7					
Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned ✓ ⑦ Pathology Non GYN Cytology Request (Path +4 hr AP Specimen SF Pathology Planned ✓ ⑦ ⑦ Immunophenotyping LPD (Immunophenoty +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned ✓ ⑦ ⑦ Immunophenotyping LPD (Immunophenoty +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned ⑦ ⑦ CSF Culture (CSF C&S) +4 hr Cerebrospinal fluid, once, Order for future visit V V 4 Schedulable Orders V V Ø IR Lumbar Puncture with Injection Routine, Reason: Intrathecal chemotherapy administration, Day 19			(Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on	Planned	
Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system	7					
AP Specimen CSF Pathology Planned CSF Pathology Planned Immunophenotyping LPD (Immunophenoty +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Immunophenotyping CSF Culture (CSF C&S) +4 hr Cerebrospinal fluid, once, Order for future visit Cerebrospinal fluid, once, Order for future visit Immunophenotyping LPD (Immunophenoty +4 hr Cerebrospinal fluid, once, Order for future visit Immunophenotyping LPD (Immunophenoty Immunophenotyping LPD (Immunophenoty +4 hr Cerebrospinal fluid, once, Order for future visit Immunophenotyping LPD (Immunophenoty Immunophenotyping LPD (Immunophenoty +4 hr Cerebrospinal fluid, once, Order for future visit Immunophenotyping LPD (Immunophenotyping	_				Planned	
Immunophenotyping LPD (Immunophenoty +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned Cerebrospinal fluid, once, Order for future visit +4 hr Cerebrospinal fluid, once, Order for future visit 4 Schedulable Orders			1	AP Specimen		
Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on Planned □ ⑦ CSF Culture (CSF C&S) +4 hr Cerebrospinal fluid, once, Order for future visit 4 △ Schedulable Orders 4 □ ⑦ IR Lumbar Puncture with Injection 8 Routine, Reason: Intrathecal chemotherapy administration, Day 19	-				Planned	
□ Image: CSF Culture (CSF C&S) +4 hr Cerebrospinal fluid, once, Order for future visit	 				Disposed	
Cerebrospinal fluid, once, Order for future visit	1				Planned	
 ✓ Schedulable Orders ☐ ☐ IR Lumbar Puncture with Injection Routine, Reason: Intrathecal chemotherapy administration, Day 19 						
IR Lumbar Puncture with Injection Routine, Reason: Intrathecal chemotherapy administration, Day 19	4 Se	che		1		
Routine, Reason: Intrathecal chemotherapy administration, Day 19						
/ersioning: Yes			[Day 19		
/ersioning: Yes				yay 15		
-	ers	sio	n	i ng: Yes		





PowerPlan: SCNAUSEA Cycles/PowerPlans: ONCS Post Chemotherapy Antiemetics (SCNAUSEA) **Changes:** Under the section For highly emetogenic agents, added a 2.5mg option for olanzapine. Juatus Component Details 😵 ONCS Post Chemotherapy Antiemetics (SCNAUSEA) (Future Pending) ⊿ Medications 😹 🕱 Link to Protocol 🕉 Revised: 1 April 2022 18 For highly emetogenic agents 🐣 aprepitant 80 mg, PO, qdaily, order duration: 2 doses or times, drug form: tab, start: T+1;0800 Days 2 and 3 Π 4 mg, PO, BID, order duration: 2 day, drug form: tab, start: T;1700 dexamethasone • Days 1 and 2 🖘 🥜 OLANZapine • 🏈 Do not use OLANZapine with prochlorperazine or metoclopramid Г 📾 🔗 prochlorperazine 5 mg, PO, qdaily, order duration: 3 doses or times, drug form: tab, start: T+1;0800 📾 🔗 metoclopramide 10 mg, PO, qdaily, order duration: 3 doses or times, drug form: tab, start: T+1;0800 3 For moderately emetogenic agents: Under the section For moderately emetogenic agents, added a 2.5mg option for olanzapine. 18 For moderately emetogenic agents: 4 mg, PO, BID, order duration: 2 day, drug form: tab, start: T;1700 dexamethasone Days 1 and 2 📾 🦪 OLANZapine • 3 Do not use OLANZapine with prochlorperazine or metoclopramide Г 69 ീ prochlorperazine 5 mg, PO, qdaily, order duration: 2 doses or times, drug form: tab, start: T+1;0800 ee 🐣 \bullet metoclopramide 10 mg, PO, qdaily, order duration: 2 doses or times, drug form: tab, start: T+1;0800 Versioning: Yes Jira: CST-162587





PowerPlan: GILEN

Cycles/PowerPlans: All associated Regimens and Powerplans

Changes:

Regimen and powerplan description updated to:

"Therapy of Advanced Hepatocellular Carcinoma Using Lenvatinib"

ONC GI GILEN (PO) (Pending)

Hide additional details

Regimen description: Therapy of Advanced Hepatocellular Carcinoma Using Lenvatinib

Versioning: No

Jira: CST-163739

PowerPlan: GISORAF

Cycles/PowerPlans: All associated Regimens and Powerplans

Changes:

Regimen and powerplan description updated to:

"Therapy for Advanced Hepatocellular Carcinoma using SORAfenib"

ONC GI GISORAF (PO) (Pending)

Hide additional details

Regimen description: Therapy for Advanced Hepatocellular Carcinoma using SORAfenib

Versioning: No

Jira: CST-163738

Jira Ticket #	CST-163739, CST-163738, CST-162587, CST-161870, CST-161173, CST-161171, CST- 161170
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Phone Support: 1-844-214-7444



